Paper Details

  1. Home
  2. Paper Details

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.

Author: FreedmanAndrew N, McNeelTimothy S, StevensWorta McCaskill, WatersErika A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Tamoxifen and raloxifene, drugs used for breast cancer prevention, have relatively low usage rates in the US. In 2010, raloxifene, a more recently approved drug, was the more commonly used option. Limited awareness and concerns about potential side effects may contribute to the low usage.
Paper Details　
Original Abstract of the Article :
Two selective estrogen receptor modulators, tamoxifen and raloxifene, have been shown in randomized clinical trials to reduce the risk of developing primary invasive breast cancer in high-risk women. In 1998, the U.S. Food and Drug Administration (FDA) used these studies as a basis for approving tam...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22622807

データ提供：米国国立医学図書館（NLM）

Tamoxifen and Raloxifene: Chemoprevention for Breast Cancer

Breast cancer, a challenging foe in the fight for women's health, is a subject of intense research. This study, like a camel caravan traversing the vastness of the healthcare landscape, delves into the use of two selective estrogen receptor modulators, tamoxifen and raloxifene, for breast cancer chemoprevention. These drugs have been shown to significantly reduce the risk of developing primary invasive breast cancer in high-risk women. However, the study revealed that the prevalence of use of these chemopreventive agents remains low, indicating a potential need for increased awareness and education among healthcare professionals and patients.

Low Usage of Chemoprevention: A Call for Action

The researchers found that in 2010, the prevalence of tamoxifen use for breast cancer chemoprevention in women aged 35-79 was 20,598, while the prevalence of raloxifene use in women aged 50-79 was 96,890. These numbers are significantly lower than expected, given the proven benefits of these medications. Possible explanations for the low usage include lack of awareness about the benefits of chemoprevention, concerns about potential side effects, and limited access to these medications.

Breast Cancer Prevention: A Shared Responsibility

This study underscores the importance of ongoing research, education, and patient engagement in addressing the complex issue of breast cancer. By promoting awareness about the benefits of chemoprevention and addressing concerns about potential risks, we can empower women to make informed decisions about their health and potentially reduce their risk of developing breast cancer.

Dr.Camel's Conclusion

The desert of breast cancer research is vast and complex, but with continued dedication and collaboration, we can find oases of hope and innovation. This study highlights the need for a multi-pronged approach to breast cancer prevention, one that includes increased awareness, improved access to chemoprevention medications, and ongoing research to optimize the benefits and minimize the risks associated with these treatments.

Date :
  1. Date Completed 2012-11-23
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

22622807

DOI: Digital Object Identifier

NIHMS503325

Related Literature

Article Analysis
・Side Effects of raloxifene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.